Recent blog posts
Myasthenic syndrome Lambert-Eaton Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Myasthenic syndrome Lambert-Eaton Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Myasthenic syndrome Lambert-Eaton strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Morphotek, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
Latest Hotspot
8 min read
Morphotek, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
Morphotek, Inc BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
Read →
Brody disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Brody disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Brody disease indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
McArdle disease exercise intolerance Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
McArdle disease exercise intolerance Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 McArdle disease exercise intolerance strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.
Read →
RYR1-related myopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
RYR1-related myopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 RYR1-related myopathy strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Merosin-deficient congenital muscular dystrophy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Merosin-deficient congenital muscular dystrophy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Merosin-deficient congenital muscular dystrophy strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with.
Read →
Multi-minicore disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Multi-minicore disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Multi-minicore disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Bethlem myopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Bethlem myopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Bethlem myopathy indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Ullrich congenital muscular dystrophy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Ullrich congenital muscular dystrophy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Ullrich congenital muscular dystrophy strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.
Read →
Multimeric Biotherapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
Latest Hotspot
8 min read
Multimeric Biotherapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
Multimeric Biotherapeutics, Inc. BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
Read →
Central core disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Central core disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Central core disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Nemaline myopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Nemaline myopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Nemaline myopathy indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →